Evidence map›Paper›PMID 37265668›Full record

ArticleOpen forum infectious diseases2023

Chris Chavtur, Weston J Staubus, Mabel Ho, Dianna E B Hergott, Annette M Seilie, Sara Healy, Patrick Duffy, Lisa Jackson, Angela Talley, Stefan H I Kappe and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

Chris ChavturMalaria Molecular Diagnostic Laboratory, Department of Laboratory Medicine and Pathology and Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, Washington, USA.
Weston J StaubusMalaria Molecular Diagnostic Laboratory, Department of Laboratory Medicine and Pathology and Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, Washington, USA.
Mabel HoMalaria Molecular Diagnostic Laboratory, Department of Laboratory Medicine and Pathology and Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, Washington, USA.
Dianna E B HergottMalaria Molecular Diagnostic Laboratory, Department of Laboratory Medicine and Pathology and Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, Washington, USA.
Annette M SeilieMalaria Molecular Diagnostic Laboratory, Department of Laboratory Medicine and Pathology and Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, Washington, USA.
Sara HealyLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
Patrick DuffyLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
Lisa JacksonKaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
Angela TalleySpero Therapeutics, Cambridge, Massachusetts, USA.
Stefan H I KappeCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Stephen L HoffmanSanaria, Rockville, Maryland, United States.
Thomas L RichieSanaria, Rockville, Maryland, United States.
James G KublinVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Ming ChangMalaria Molecular Diagnostic Laboratory, Department of Laboratory Medicine and Pathology and Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, Washington, USA.
Sean C MurphyMalaria Molecular Diagnostic Laboratory, Department of Laboratory Medicine and Pathology and Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, Washington, USA.
University of Washington · USCenter for Infectious Disease Research · USSanaria · USFred Hutch Cancer Center · USInfectious Disease Research Institute · USKaiser Permanente Washington Health Research Institute · USSeattle Children's Hospital · USSpero Therapeutics (United States) · US

Funding

Pre-erythrocytic malaria vaccines: Discovery and Clinical DevelopmentZIAAI001135 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DUFFY, PATRICK · 2010 to 2025
$6.4M
Assessment of whole organism vaccinations in Malian AdultsZIAAI001170 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DUFFY, PATRICK · 2012 to 2024
$4.8M
6 · The paper itself

Abstract

Background: Sensitive molecular assays, such as quantitative reverse-transcription polymerase chain reaction (qRT-PCR) of Methods: For this analysis, 18S rRNA qRT-PCR data were compiled from 127 Results: The median time to biomarker clearance was 3 days (interquartile range, 3-5 days), while the median time to TBS clearance was 1 day (1-2 days). Time to biomarker clearance increased with the parasite density at which treatment was initiated. Parasite density did not have a significant effect on TBS clearance. Conclusions: The

Indexed as

18S ribosomal RNAbiomarker clearancecontrolled human malaria infectionPlasmodium‌RT-PCR

Identifiers

PMID37265668
PMCPMC10230565
OpenAlexW4365451731

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.